Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR | The ABCs of ADCs: From PK to PD 1 days 1 hours 11 mins 53 secs REGISTER NOW

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • Editor’s highlights from the European Bioanalysis Forum 2025
  • Biopharma’s new blueprint: why partnering and M&A are mission-critical
  • Merck to buy Cidara Therapeutics, adding late-stage antiviral drug to its portfolio

Related tags

antibody Bio-rad biotherapeutics technology
Previous article Next article

Related articles

2 SEP 2014 CLINICAL
New optical device may improve skin cancer diagnostics
10 OCT 2011 COLLABORATIONS AND MERGERS
2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings from Audits and Inspections
20 NOV 2014 CHROMATOGRAPHY
How can we improve ion-exchange separations in LC?
4 MAR 2014 GENERAL INTEREST
Genotyping assay reported for HPV identification
31 MAR 2016 MS (LC–MS/MS, HRMS, IMS)
Internal Standard Considerations for Protein Therapeutic Bioanalytical LC-MS/MS Assays
20 MAY 2014 GENERAL INTEREST
Is computer-aided design the future of lab-on-a-chip production?
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone